Pediatrics II: Retinopathy of Prematurity
My Session Status
At the end of this session, participants will be able to:
- Apply ROP screening guidelines specific to Canada
- Describe pathophysiology of ROP and future potential screening tools
- Demonstrate knowledge of telescreening for ROP
- Apply knowledge from complex ROP case discussion to daily practice
CanMEDS: Heath Advocate, Medical Expert
Elementy podrzędne
Author’s Name(s): Alicia Liu, Oi Ying Wong, Man Hin Leung, Connie Lai, Thomas Lam, Wai-Ching LamAuthor’s Disclosure Block: Alicia Liu, none; Oi Ying Wong, none; Man Hin Leung, none; Connie Lai, none; Thomas Lam, none; Wai-Ching Lam, noneAbstract BodyRetinopathy of prematurity (ROP) is the leading cause of preventable childhood blindness. Tear protein biomarkers identified from next-generation label-free proteomics may offer ...
Author’s Name(s): Farnaz Javadian, Wilma Hopman, Faiza Khurshid, Christine LawAuthor’s Disclosure Block: Farnaz Javadian, none; Wilma Hopman, none; Faiza Khurshid, none; Christine Law, noneAbstract BodyPurpose: Steroid treatment can be crucial in treating morbidity and mortality in preterm infants. The literature describes differing effects of antenatal (ANS) versus postnatal steroids (PCS) in the development of retinopathy ...
Author’s Name(s): Felicia Tai, Yasmin Jindani, Kourosh SabriAuthor’s Disclosure Block: Felicia Tai, none; Yasmin Jindani, none; Kourosh Sabri, noneAbstract BodyPurpose: Retinopathy of prematurity (ROP) is a proliferative retinal vascular disease affecting many premature infants, with 5-10% of untreated ROP leading to permanent blindness. Many models currently exist for screening premature infants for treatment-requiring ROP....
